Genevieve Regal, PharmD, HC-MBA

Through ongoing quarterly targeted medication counseling follow-up sessions, the pharmacist may identify ART noncompliance.

On August 23, 2018, the FDA approved lanadelumab-flyo (Takhzyro; Shire) for the prophylaxis treatment and prevention of hereditary angioedema (HAE) in patients 12 years or older.

Based on 2017 FDA research, the delayed market launch of nine biosimilars represented $4.5 billion in potential savings.